Top 4 Ways to Trade a Virus That’s No Longer Confined

0
365

The coronavirus just will not die.

“This isn’t confined to a handful of states anymore,” says former US FDA Commissioner Dr. Scott Gottlieb.  “It’s going to be difficult now to get this under control.”

The U.S. saw 45,000 new cases just yesterday.

The global number is now up to nearly 10 million infections.

States are starting to pause reopening plans.

Hundreds of thousands of people are being infected by the day.  Thousands have died.  There’s even fear global economies may need to be shut down again.

Right now:

  • The U.S. is up to 2.38 million cases
  • Brazil is up to 1.18 million
  • Russia is up to 613,148
  • India jumped to 473,105
  • The UK is now to 308,337

Unfortunately, there’s no immediate-term answer on how to stop it.

Johns Hopkins University is warning of another severe breakout.

“There is a new wave coming in parts of the country,” Eric Toner, a senior scholar for Health Security said, as quoted by Bloomberg. “It’s small and it’s distant so far, but it’s coming.”

For investors looking for investing opportunities, some of the top stocks include:

Alpha Pro Tech (APT) just doubled, as some states order the use of face masks.  California Gov. Gavin Newson just tweeted, “Californians are now REQUIRED to wear face coverings in public spaces.”

Inovio Pharmaceuticals (INO) is soaring after receiving a $71 million contract from the US Department of Defense to scale up the manufacturing of CELLECTRA 3PSP smart device and the procurement of CELLECTRA 2000 devices, which are used to deliver INO-4800 directly into the skin.

Moderna Inc. (MRNA) just advanced late-stage development of its coronavirus vaccine. Better, it just finalized the Phase 3 study protocol based on feedback from the U.S. FDA.

Novavax Inc. (NVAX) is up after being awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M adjuvant.

 

Advertisement

LEAVE A REPLY

Please enter your comment!
Please enter your name here